Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Inclusion Criteria: * Diagnosis CLL/small lymphocytic lymphoma (SLL) and be untreated * Patients must have an indication for treatment by 2018 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Patients of childbearing potential must be willing to practice highly effective birth control during treatment and for 2 days after the last dose of acalabrutinib or 18 months after the last dose of obinutuzumab, whichever is later * A negative urine pregnancy test (within 7 days of day 1) is required for women with childbearing potential * Adequate renal and hepatic function as indicated by all of the following: Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) except for patients with bilirubin elevation due to Gilbert's disease who will be allowed to participate * An alanine transferase (ALT) =\< 2.5 x ULN * An estimated creatinine clearance (CrCl) of \> 30 mL/min, as calculated by the Cockcroft-Gault equation unless disease related * Free of prior malignancies for 2 years with exception of patients diagnosed with basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast who are eligible even if they are currently treated or have been treated and/or diagnosed in the past 2 years prior to study enrollment. If patients had another malignancy of indolent behavior in the past 2 years prior to study enrollment that is expected to be cured…